No Data
Good performance, cold stock price, why is Médecins Opticiens "good but not popular" (06622)?
Behind the abnormal stock price performance, is it due to the inadequate market potential of the company's new drugs, the underperformance of the fundamentals, or is there another hidden mystery?
Department of Health: The "1+" approval mechanism will be expanded to all new drugs starting from November, embodying the concept of "Hong Kong, a Good Drug Harbor".
The Department of Health announced today (25th) that, in accordance with the measures announced in the Chief Executive's Policy Address for 2024, the "1+" approval mechanism will be expanded to all new drugs starting from November 1 this year, including vaccines and advanced therapy products, embodying the concept of "good medicine available in Hong Kong." Expanding the "1+" mechanism can attract more new drugs from around the world to register in Hong Kong, providing patients with more choices, strengthening the local drug regulatory capacity, promoting the development of relevant hardware and software, and talent, and further moving towards the "first-level approval." The government will innovate the system in conjunction with technological innovation to develop Hong Kong into an international medical innovation hub. According to the "Pharmacy and Poisons Ordinance".
Hong Kong stock abnormal | MegaEyes-B (06622) opens more than 9% higher, NVK002 nearsightedness treatment clinical trial shows positive results.
Megain Medical-B (06622) opened more than 9% higher, as of the publication, rose by 9.56%, at 1.49 Hong Kong dollars, with a turnover of 0.2213 million Hong Kong dollars.
Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results
Zhaoke Ophthalmology-B(06622.HK): The positive top-line results of the two-year China Phase III clinical trial (CHINA CHAMP) of NVK002 for treating worsening myopia in children.
On October 23, Cholonhui announced that Zeoke Ophthalmology-B (06622.HK) released the topline results of the two-year Phase III clinical trial ("China CHAMP") of NVK002 (one of the company's core products). After two years of treatment, the study analysis showed that the NVK002 eye drop group (0.01% and 0.02% doses) had statistically significant differences in the main efficacy indicators compared to the placebo group, with the NVK002 eye drop group outperforming the placebo group and showing dose dependency. The safety of both doses of NVK002 is good, with patient compliance.
Express News | Zaokai Ophthalmology: The clinical trial of NVK2 for myopia treatment shows positive results.
No Data
No Data